Codeine Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is supplied as codeine phosphate hemihydrate, a white or almost white crystalline powder with a molecular weight of 406.37 g/mol and a codeine base content governed by compendial assay. The product is available under the trade-neutral identifier “Codeine Phosphate Hemihydrate—Veterinary Grade API”; no universal proprietary model number exists, and a manufacturer-specific lot code typically encodes the salt form, monograph version, production site, and year of manufacture. Where a supplier catalog lists a model designation, it is an internal commercial identifier and does not denote a different chemical entity. Veterinary-grade documentation includes a certificate of analysis, a TSE/BSE statement, an elemental impurity risk assessment, and a nitrosamine risk evaluation. The hemihydrate form is selected for aqueous dosage forms because of its freely soluble behavior in water; the phosphate salt also provides acceptable stability for tableting and capsule filling compared with codeine base, which has lower aqueous solubility. The API is controlled as a scheduled substance in national regulations, and the chemical identity is identical whether the material is allocated to human or veterinary use where the same pharmacopoeial monograph is applied.

What Compendial Acceptance Criteria Apply to Codeine Phosphate Hemihydrate?

Compendial compliance for the veterinary API is assessed using the current Ph. Eur. and USP-NF Codeine Phosphate monographs where the destination market requires compendial alignment. The identification suite includes infrared absorption concordant with the reference spectrum, a phosphate reaction by Ph. Eur. 2.3.1, and a retention time match against the reference standard in the HPLC related-substances procedure. Assay by titration or HPLC on the dried substance falls within 98.5–101.0%; the hemihydrate water content is controlled at 6.0–7.5% by Karl Fischer titration according to Ph. Eur. 2.5.12. Sulfated ash is limited to ≤0.1% by Ph. Eur. 2.4.14. Residual solvents are controlled under Ph. Eur. 5.4 and USP <467>; no Class 1 residual solvent is used or detected, and Class 2 solvents, if any, are below the concentration limits stated in the monograph. Elemental impurities are assessed using the risk-based approach of Ph. Eur. 5.20 and USP <232>/<233>.

Sieve analysis and laser diffraction data are more informative than compendial tests for downstream unit operations. A direct-compression grade may show a D90 of 150–250 µm on a Malvern Mastersizer 3000 with dry dispersion at 1.5 bar, while a premix or low-dose capsule grade is often micronized to D90 30–60 µm. Bulk density ranges from 0.45 g/mL to 0.65 g/mL, and tapped density from 0.60 g/mL to 0.85 g/mL; these values produce a Carr index of 20–30, indicating passable-to-poor flow that may require glidants. The powder should be stored at 15–25 °C in moisture-tight HDPE drums with desiccant; if ambient relative humidity exceeds 60% for more than 4 h, pre-drying at 40–50 °C to water content below 5.0% is required before direct compression.

Batch-to-batch variance in particle size is a more common cause of content uniformity drift than assay variability. When the D90 of the API changes from 180 µm to 240 µm between lots, direct-compression tablets at 2% w/w drug load can exhibit relative standard deviations above 6.0% if no screen deagglomeration is performed. A comil equipped with a 0.500 mm round screen and round bar impeller at 1500 rpm is used before blending to reduce agglomerates and narrow the particle-size distribution. This step is especially important for capsules and premix blends where the API fraction is below 5% w/w. Preformulation compatibility screening should include magnesium stearate, lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and citrate buffers. Differential scanning calorimetry of binary mixtures at 10% w/w drug load shows dehydration above 80 °C; no interaction is inferred unless the dehydration peak shifts by more than 5 °C. Forced-degradation studies under ICH Q1B using a xenon lamp at 1.2 million lux-hours and 200 Wh/m² UV confirm light sensitivity; amber packaging is required for solid oral and liquid dosage forms.

From direct compression to terminal sterilization—processing boundaries across dosage forms

Tablets containing codeine phosphate hemihydrate are generally produced by wet granulation when the drug load exceeds 30% w/w because direct compression of the pure salt can cause picking and sticking on steel tooling at compression pressures above 18 kN. A high-shear granulator with impeller tip speed 4–6 m/s and chopper speed 1500–2000 rpm, followed by fluid-bed drying at inlet air temperature 55–65 °C to final granule moisture of 2–4% w/w, yields granules with bulk density 0.55–0.70 g/mL. Compression on a rotary tablet press at 30–60 rpm with precompression force 2–4 kN and main compression force 8–18 kN produces tablet hardness 60–90 N, friability below 0.8% per USP <1216>, and disintegration under USP <701> with water at 37 °C within 15 min for uncoated tablets.

Hard capsule fills use the freely water-soluble phosphate salt to obtain rapid dissolution. With a fill containing 5–10% w/w croscarmellose sodium and 0.5% w/w magnesium stearate, dissolution in water at 37 °C using USP <711> apparatus 2 at 50 rpm typically reaches not less than 80% of label claim in 15 min for an immediate-release formulation. Overblending with magnesium stearate beyond 10 min reduces tensile strength and slows dissolution because of hydrophobic film coverage on the soluble salt surface.

Oral powders and granules are prepared by geometric dilution in a V-blender at 25 rpm for 10–15 min when the API fraction is below 5% w/w. The carrier, usually mannitol or sucrose, is pre-dried at 60 °C to moisture ≤1.0% to avoid agglomeration; blend uniformity is verified by sampling 10 locations and assaying for codeine phosphate with recovery 95–105% and relative standard deviation below 5.0%. Medicated premix is produced in a low-shear ribbon blender by spraying an aqueous codeine phosphate solution onto lactose monohydrate or cornstarch. The carrier particle-size distribution should remain within a 3:1 ratio to the final feed to limit segregation; if the premix D50 is 80–120 µm and the feed D50 is 300–500 µm, stratification can occur during transfer. Blend uniformity is assessed by recovery at 10 sampling points. Dicalcium phosphate carriers are not recommended because free calcium can form poorly soluble calcium phosphate species and reduce codeine availability in aqueous extraction.

For injectable products, codeine phosphate is dissolved at 10–30 mg/mL in Water for Injection, buffered with citrate or phosphate at pH 3.5–5.0, and adjusted to 280–320 mOsm/kg with sodium chloride. The solution is filtered through a 0.22 µm polyethersulfone membrane and may be terminally sterilized at 121 °C for 15 min after confirming pH drift remains under 0.2 units and no visible precipitation occurs; otherwise, aseptic filtration is used. Particulate matter is controlled under USP <788> for injections. Solutions for oral use in companion animals may contain benzyl alcohol or sodium benzoate; pH is maintained between 3.0 and 5.0 to minimize precipitation of the free base. Long-term storage at 25 °C/60% RH in amber glass or HDPE containers requires light protection because codeine undergoes photolytic degradation.

Published pharmacokinetic data in dogs indicate that codeine is O-demethylated to morphine only to a limited and variable extent; therefore, the antinociceptive effect is less predictable than that of direct-acting µ-opioid receptor agonists. In equine practice, codeine is more commonly encountered as an antitussive in oral powders or granules than as an injectable analgesic; published data for perioperative use in horses are limited. Differences from morphine sulfate pentahydrate and butorphanol tartrate are therefore not solely potency differences but also metabolic activation dependence. In cats, the species-specific conjugation capacity and the potential for adverse central nervous system excitation require dose caution; published efficacy data for codeine in cats as an analgesic are limited. Premix applications are restricted to non-food-producing species, especially equine antitussive formulations where national law allows.

When Codeine Phosphate Hemihydrate Is Compared with Morphine Sulfate, Butorphanol, and Tramadol in Veterinary Formulation Work

Comparative selection among opioid APIs is driven by salt solubility, receptor profile, and metabolic activation. Codeine phosphate hemihydrate has a molecular weight of 406.37 g/mol and is freely soluble in water; morphine sulfate pentahydrate has a molecular weight of 758.83 g/mol and is soluble in water but is formulated at lower concentrations for injection because of potency. Butorphanol tartrate has a molecular weight of 477.55 g/mol and exhibits κ-opioid receptor agonist and µ-opioid receptor antagonist activity; tramadol hydrochloride has a molecular weight of 299.84 g/mol and acts as a serotonin-norepinephrine reuptake inhibitor with an analgesic metabolite. Codeine and tramadol both require metabolic O-demethylation for strong µ-opioid receptor agonist activity, whereas morphine and butorphanol do not have the same prodrug dependence.

Because of the hemihydrate water and phosphate ion, codeine phosphate hemihydrate is incompatible with calcium-containing carriers in premix and with strong alkalis in aqueous solution; the free base precipitates above pH 6.0 in concentrated solutions. By contrast, morphine sulfate and tramadol hydrochloride are more tolerant of neutral pH in compounded oral liquids, though light and oxygen sensitivity require similar protective packaging. Codeine has a narrower veterinary dossier than direct-acting opioids for acute perioperative pain, but its oral salt solubility and mild antitussive profile make it technically suitable for tablet, granule, and solution forms where national prescribing rules permit use.

Controlled-substance handling is an operational boundary that distinguishes codeine from non-scheduled veterinary APIs. The API must be received into a locked, access-controlled vault, reconciled by lot and weight at each transfer, and stored at 15–25 °C in moisture-tight containers. In the United States, codeine is a Schedule II controlled substance under the Controlled Substances Act; in the European Union, national narcotics legislation applies. Use in food-producing animals is not authorized, and compounding for companion animals is limited to a valid veterinarian-client-patient relationship. Destruction or return of expired sub-lots must follow national controlled-substance waste regulations. These supply-chain requirements, rather than the pharmacopoeial chemistry, are the main difference between codeine veterinary-grade API and non-controlled opioid alternatives.